Epidemiology and control of antibiotic resistance in the intensive care unit

Current Opinion in Infectious Diseases

Volumn 17, Issue 4, 2004, Pages 309-316

  Carlet, Jean ^a   Ali, Adel Ben ^a   Chalfine, Annie ^a  

^a SAINT JOSEPH HOSPITAL   (France)

Author keywords

Antibiotic resistance; Cycling; Intensive care unit; Methicillin resistant Staphylococcus aureus; Selective digestive decontamination

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFEPIME; CEPHALOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; GLYCOPEPTIDE; KETOLIDE; LINEZOLID; LIPOPEPTIDE; NEOMYCIN; PENEM DERIVATIVE; QUINOLONE; SULFADIAZINE SILVER; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CONTROL; EPIDEMIOLOGY; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMPORT DISEASE; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INOCULATION; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PREVENTIVE MEDICINE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SCREENING TEST;

BACTEREMIA; CANADA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; EUROPE; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; UNITED STATES;

EID: 3843146132     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000136927.29802.68     Document Type: Review

References (145)

1. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22:551-556.
2. Canton R, Coque TM, Baquero F. Multi-resistant Gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 2003; 16:315-325.
3. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36:S11-S23.
4. Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 11:154-160.
5. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-R83.
6. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-1118. Old drugs can still work!
7. Borg MA. Bed occupancy and overcrowding as determinant factors in the incidence of MRSA infections within general ward settings. J Hosp Infect 2003; 54:316-318.
8. Annane D, Aegerter P, Jars-Guincestre, et al. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003; 168:165-172. Strong and large data on septic shock with important data on resistance patterns of responsible bacteria.
9. Turnidge J. Impact of antibiotic resistance on the treatment of sepsis. Scand J Infect Dis 2003; 35:677-682.
10. Bonten MJM, Mascini EM. The hidden faces of the epidemiology of antibiotic resistance. Intensive Care Med 2003; 29:1-2.
11. McGowan JE, Hill HA, Volkova NV, et al. Does antimicrobial resistance cluster in individual hospitals? J Infect Dis 2002; 186:1362-1365.
12. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 6:67-71.
13. Hanberger H, Erlandsson M, Burman LG, et al. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 2004; 36:24-30.
14. Friedland I, Stinson L, Ikaiddi M, et al. Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect Control Hosp Epidemiol 2003; 24:607-612. Large international and multicentre study.
15. Johnson AP, Henwwod C, Mushtaq S, et al. Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. J Hosp Infect 2003; 54:179-187.
16. Sorberg M, Farra A, Ransjo U, et al. Different trends in antibiotic resistance rates at a university teaching hospital. Clin Microbiol Infect 2003; 9:388-396.
17. Hoogkamp-Korstanje JA, Roelofs-Willemse J, Susceptibility Surveillance Study Group. Antimicrobial resistance in Gram-negative bacteria from Intensive Care Units and Urology Services. A nationwide study in the Netherlands 1995-2000.
18. Mallaval FO, Carricajo A, Martin I, et al. Epidemic outbreaks involving Staphylococcus aureus with reduced sensitivity to glycopeptides. Pathol Biol 2003; 51:469-473.
19. Torregrossa MV, Cannova L, Sucameli M, et al. Dispersal of methicillin resistant Staphylococcus aureus (MR) in a burn intensive care unit. Ann Ig 2003; 15:107-110.
20. Kampf G, Adena S, Ruden H, et al. Inducibility and potential role of MecA-gene-positive oxacillin susceptible Staphylococcus aureus from colonized healthcare workers as a source for nosocomial infections. J Hosp Infect 2003; 54:124-129.
21. Montesinos I, Salido E, Delgado T, et al. Epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital in the Canary Islands. Infect Control Hosp Epidemiol 2003; 24:667-672.
22. Cooper C, Ochota MA. Surveillance of hospital-acquired methicillin-resistant Staphylococcus aureus in South Australia. Commun Dis Intell 2003; 27:S92-S96.
23. Marshall C, Harrington G, Wolfe R, et al. Acquisition of methicillin-resistant Staphylococcus aureus in large intensive care unit. Infect Control Hosp Epidemiol 2003; 24:322-326.
24. Cheng-Hsin L, Ron-Bin H, Shan-Chwen C, et al. Poststernotomy mediastinitis due to Methicillin-resistant Staphylococcus aureus endemic in a hospital. Clin Infect Dis 2003; 37:679-684.
25. Lucet JC, Chevret S, Durand-Zaleski I, et al. Prevalence and risk factors for carriage of Methicillin-resistant Staphylococcus aureus at admission to the intensive care unit. Arch Intern Med 2003; 163:181-188. Good study showing the high incidence of patients carrying MRSA and supporting screening and isolation.
26. Cartolaw GL, Cheron M, Benatid D, et al. Methicillin-resistent Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004; 10:448-451.
27. Patel R. Clinical impact of vencomycin-resistant enterococci. J Antimicrob Chemother 2003; 51:13-21.
28. Martinez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905-1912.
29. Hallgren A, Saeedi B, Nilsson M, et al. Genetic relatedness among Enterococcus faecalis with transposon-mediated high-level gentamicin resistance in Swedish intensive care units. J Antimicrob Chemother 2003; 52:162-167.
30. Campanile F, Bartoloni A, Bartalesi F, et al. Molecular alteations of Van A element in vancomycin-resistant enterococci isolated during a survey of colonized patients in an Italian intensive care unit. Microb Drug Resist 2003; 9:191-199.
31. Werner G, Klare I, Spencker FG. Intra-hospital dissemination of quinupristin/ dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003; 52:113-115.
32. Calfee DP, Giannetta ET, Durbin LJ, et al. Control of endemic Vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis 2003; 37:326-332.
33. Lai KK, Fontecchio SA, Kelley AL, et al. The changing epidemiology of vancomycin-resistant Enterococci. Infect Control Hosp Epidemiol 2003; 24:264-268.
34. Warren DK, Kollef MH, Seiler SM, et al. The epidemiology of vancomycin-resistant Enterococcus colonization in a medical intensive care unit. Infect Control Hosp Epidemiol 2003; 24:257-263.
35. Mohammedi I, Ploin D, Duperret S, et al. Risk factors for piperacillin/tazobactam-resistant Escherichia Coli in ICU patients: a clinical study. Intensive Care Med. 2003; 29:1164-1168.
36. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States 1998 to 2001. Antimicrob Agents Chemother 2003; 47:1681-1688.
37. Karlowsky JA, Jones ME, Thornsberry C, et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998-2001. Antimicrob Agents Chemother 2003; 47:1672-1680.
38. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiefe pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32. Nice international study on an emerging mechanism of resistance.
39. Bertrand X, Hocquet D, Boisson K, et al. Molecular epidemiology of Enterobacteriaceae producing extended-spectrum beta-lactamase in a French university-affiliated hospital. Int J Antimicrob Agents 2003; 22:128-133.
40. Hernandez JR, Pascual A, Canton R, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals (GEIH-BLE Project 2002). Enferm lnfecc Microbiol Clin 2003; 21:77-82.
41. Friedland I, Stinson L, Ikaiddi M, et al. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acineobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000. Diagn Microbiol Infect Dis 2003; 45:245-250.
42. Maniatis AN, Pournaras S, Orkopoulou S, et al. Multiresistant Acinetobacter baumannii isolates in intensive care units in Greece. Clin Microbiol Infect 2003; 9:547-553.
43. Bayat A, Shaaban H, Dodgson A, et al. Implications for Burns Unit design following outbreak of multiresistant Acinetobacter infection in ICU and Burns Unit. Burns 2003; 29:303-306.
44. Smolyakov R, Borer A, Riesenberg K, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54:32-38.
45. Barbolla RE, Centron D, Di Martino A, et al. Identification of an epidemic carbapenem-resistant Acinetobacter baumannii strain at hospitals in Buenos Aires City. Diagn Microbiol Infect Dis. 2003; 45:261-264.
46. Wu TL, Chia JH, Su LH, et al. Dissemination of extended-spectrum beta-lactamase-producin Enterobacteriaceae in pediatric intensive care units. J Clin Microbiol 2003; 41:4836-4838.
47. Berthelot P, Grattard F, Fascia P, et al. Implication of a healthcare worker with chronic skin disease the transmission of an epidemic strain of methicillin-resistant Staphylococcus aureus in a pediatric intensive care unit.
48. Keyserling HL, Sinkowitz-Cochran RL, Harris JM 2nd, et al. Vancomycin use in hospitalized pediatric patients. Pediatrics 2003; 112:104-111.
49. Aurangzeb B, Hameed A. Neonatal sepsis in hospital-born babies: bacterial isolates antibiotic susceptibility patterns. J Coll Physicians Surg Pak 2003; 13:629-632.
50. Toltzis P. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit. Minerva Pediatr 2003; 55:385-393.
51. Maury L, Cantagrel S, Cloarec S, et al. Study of correlations between antibiotics prescriptions and guidelines in a neonatal intensive care unit. Arch Pediatr 2003; 10:876-881.
52. Saiman L, Cronquist A, Wu F, et al. An outbreak of methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24:317-321 (comment in Infect Control Hosp Epidemiol 2003; 24:314-316).
53. Saiman L, Cronquist A, Wu F, et al. An outbreak of methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24:317-321 (comment in Infect Control Hosp Epidemiol 2003; 24:314-316).
54. Center KJ, Reboli AC, Hubler R, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus waerneri. J Clin Microbiol 2003; 41:4660-4665.
55. Tekerekoglu MS, Durmaz R, Ayan M, et al. Analysis of an outbreak due to Chryseobacterium meningosepticum in a neonatal intensive care unit. New Microbiol 2003; 26:57-63.
56. Shiojima T, Ohki Y, Nako Y, et al. Immediate control of a methicillin-resistant Staphylococcus aureus outbreak in a neonatal intensive care unit. J Infect Chemother 2003; 9:243-247.
57. Aiello AE, Cimiotti J, Della-Latta P, et al. A comparison of the bacteria found on the hands of homemakers and neonatal intensive care unit nurses. J Hosp Infect 2003; 54:310-315.
58. Kikuchi K. Genetic basis of neonatal methicillin-resistant Staphylococcus aureus in Japan. Pediatr Int 2003; 45:223-229.
59. Dent A, Toltzis P. Descriptive and molecular epidemiology of Gram-negative bacilli infections in the neonatal intensive care unit. Curr Opinion Infect Dis 2003; 16:279-283.
60. Singh K, Gavin PJ, Vescio T, et al. Microbiologic surveillance using nasal cultures alone is sufficiant for detection of methicillin-resistant Staphylococcus aureus isolates in neonates. J Clin Microbiol 2003; 41:2755-2757.
61. Santucci SG, Gobara S, Santos CR. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 2003; 53:6-13.
62. Song X, Srinivasan A, Plaut D, et al. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003; 24:251-256.
63. Combes A, Trouillet JL, Joly-Guillou ML, et al. The impact of methicillin resistance on the outcome of poststernotomy mediastinitis due to Staphylococcus aureus. Clint Infect Dis 2004; 38:822-829.
64. Howard DH, Scott RD II, Packard RI, et al. The global impact of drug resistance. Clin Infect Dis 2003; 15:S4-S10.
65. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with Methicillin-resistant and Methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-59. Interesting meta-analysis on a still very controversial topic.
66. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-1437.
67. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: meta-analysis. Infect Control Hosp Epidemiol 2003; 24:690-698.
68. Peres-Bota D, Rodriguez H, Dimopoulos G. Are infections due to resistant pathogens associated with a worse outcome in critically ill patients? J Infect 2003; 47:307-316. Good paper showing that attributable mortality of resistant microorganisms is very small.
69. Kollef MH. The importance of appropriate initial antibiotic therapy for hospital-acquired infections. Am J Med 2003; 115:529-535.
70. Iregui M, Ward S, Sherman G. Clinical importance of delays in the initiation of appropriate antibiotic treament for ventilator-associated pneumonia. Chest 2002; 122:262-268.
71. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31:462-467.
72. Dupont H, Mentec H, Sollet P, et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362.
73. Meyer E, Jonas D, Schwab F. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection 2003; 31:208-215.
74. Vandenesch F, Naimi T, Enright MC. Community-acquired Methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9:978-984.
75. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753-759.
76. Daum RS, Ito T, Hiramatsu K, et al. A novel Methicillin-resistance cassette in community-acquired Methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002; 186:1344-1347.
77. Chang S, Sievert DM, Hageman JC, et al. Infection with Vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-1347. The first Staphylococcus aureus resistant to glycopeptides. A dramatic cooperation between Enterococcus and Staphylococcus!
78. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48j:275-280. A second case of S. aureus fully resistant to vancomycin.
79. Ho PL, for the Hong Kong intensive care unit antimicrobial resistance study (HK-ICARE) group. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant Gram-negative bacilli, and vancomycin resistant enterococci before and after intensive care unit admission. Crit Care Med 2003; 31:1175-1182.
80. Martinez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905-1912.
81. Srinivasan A, Wolfenden LL, Xiaoyan S, et al. An outbreak of Pseudomonas aerugmosa infections associated with flexible bronchoscopes. N Engl J Med 2003; 348:221-227.
82. Kirschke DL, Jones TF, Craig AS, et al. Pesudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med 2003; 348:214-220.
83. Schultsz C, Meester HH, Kranenburg AM. Ultra-sonic nebulizers as a potential source of methicillin-resistant Staphylococcus aureus causing an outbreak in a university tertiary care hospital. J Hosp Infect 2003; 55:269-275.
84. Gras-Le Guen C, Lepelletier D, Debillon T, et al. Contamination of a milk bank pasteuriser causing a Pseudomonas aeruginosa outbreak in a neonatal intensive care unit. Arch Dis Child Fetal Neonatal 2003; 88:F434-F435.
85. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-121.
86. Vincent JL, Bihari D, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: The results of the EPIC study. JAMA 1995; 274:639-644.
87. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of colonization pressure in the spread of vancomycin resistant enterococci: an important infection control variable. Arch Intern Med 1998; 25:1127-1132.
88. Merrer J, Santoli F, Appere de Vecchi C, et al. Colonization pressure and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000; 21:718-723.
89. Monnet DL, Hemborg HD, Andersen SR, et al. Surveillance of antimicrobial resistance in Denmark. Euro Surveill 2000; 5:129-132.
90. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-888.
91. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistant among Enterobacteriaceae isolates from impatients and outpatients, 1989-2000: differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38:655-662.
92. Kampf G, Jarosch R, Ruden H. Limited effectiveness of chlorhexidine based hand disinfectant against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1998; 38:297-303.
93. Gortner L, Borkhardt A, Reiss I, et al. Higher disinfectant resistance of nosocomial isolates of Klebsiella oxytoca: indicator organisms in disinfectant testing are not reliable. J Hosp Infect 2003; 53:153-155.
94. Pirnay JP, De Vos D, Cochez C, et al. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 2003; 41:1192-1202.
95. Kollef MH. Selective digestive decontamination should not be routinely employed. Chest 2003; 123:4643-4685.
96. Van Saene HKF, Petros AJ, Ramsay G, et al. All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth. Intensive Care Med 2003; 29:677-690.
97. Leone M, Albanese J, Antonini F, et al. Long-term (6-year) effect of selective digestive decontamination on antimicrobial resistance in intensive car, multiple-trauma patients. Crit Care Med 2003; 31:2090-2095. Survey showing a very limited effect of selective digestive decontamination upon resistance on a 6-year period.
98. De Jonghe E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003; 362:1011-1016. Excellent randomized trial showing that resistance to antibiotics is decreased in the selective digestive decontamination unit (randomized trial comparing a selective digestive decontamination unit and a conventional one).
99. Bonten MJ, Brun-Buisson C, Weinstein RA. Selective decontamination of the digestive tract: to stimulate or stifle? Intensive Care Med 2003; 29:672-676.
100. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37:180-186. A perfect example of a multifaceted, effective and cost-saving program.
101. Geissler A, Gerbeaux P, Granier I, et al. Rational use of antibiotics in the intensive care unit: impact of microbial resistance and costs. Intensive Care Med 2003; 29:49-54.
102. Corona A, Raimondi F. Infection control and prevention in intensive care: environmental aspects. Minerva Anestesiol 2003; 69:308-314.
103. Kotilainen P, Routamaa M, Peltonen R, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis 2003; 9:169-175.
104. Wang SH, Sheng WH, Chang YY, et al. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect 2003; 53:97-102.
105. Hall CS, Ost DE. Effectiveness of programs to decrease antimicrobial resistance the intensive care unit. Semin Respir Infect 2003; 18:112-121.
106. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31:S25-S28.
107. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
108. Torres A, Cartel J. Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia. Eur Respir J 2001; 17:1034-1045.
109. Struelens MJ. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis 2003; 16:305-307.
110. Shankar PR, Partha P, Shenoy M. Investigation of antimicrobial use pattern in the intensive treatment unit of a teaching hospital in western Nepal. Am J Infect Control 2003; 31:410-414.
111. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621-630.
112. Ost DE, Hall CS, Gnanaraj J, et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003; 168:1060-1067.
113. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873. Very complete and broad guidelines with, in particular, and in addition to the therapy of sepsis, new proposals for antibiotic management of critically ill patients.
114. Kollef MH. Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med 2003; 29:147-149.
115. Kollef MH. An empirical approach to the treatment of multidrug-resistant ventilator associated pneumonia. Clin Infect Dis 2003; 36:1119-1121.
116. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003; 290:2588-2598. Outstanding randomized controlled trial showing that 7 days are, in most cases, as efficient as 2 weeks in the treatment of ventilator-associated pneumonia.
117. Leroy O, Jaffre S, D'Escrivan T, et al. Hospital-acquired pneumonia: risk factors for antimicrobial-resistant causative pathogens in critically ill patients. Chest 2003; 123:2034-2042.
118. Dugan HA, MacLaren R, Jung R. Duration of antimicrobial therapy for nosocomial pneumonia possible strategies for minimizing antimicrobial use in intensive care units. J Clin Pharm Ther 2003; 28:123-129.
119. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004; 38:670-677.
120. Van Der Zee A, Sterr N, Thijsssen E, et al. Use of multienzyme multiplex PCR amplified fragment length polymorphism typing in analysis of outbreaks of multiresistant Klebsiella pneumoniae in an intensive care unit. J Clin Microbiol 2003; 41:798-802.
121. Andreoni M. Phenotypic resistance testing. Scand J Infect Dis Suppl 2003; 35:35-36.
122. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29:1101-1108.
123. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162:837-843.
124. Gruson D, Hilbert G, Vargas F. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003; 31:1908-1914.
125. Fridkin SK. Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 2003; 36:1438-1444.
126. Hughes MG, Evans HL, Chong TW, et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 2004; 32:53-60.
127. Toltzis P, Dul MJ, Hoyen C, et al. The effect of antibiotic rotation on colonization with antibiotic resistant bacilli in a neonatal intensive care unit. Petiatrics 2002; 110:707-711.
128. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268-1274.
129. Trouillet JL, Chastre J, Vuagnat A. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539.
130. Nseir S, Di Pompéo C, Pronnier P, et al. Infections broncho-pulmonaires nosocomiales précoces et tardives en réanimation. Presse Med 2003; 32:1111-1115.
131. Koeman M, Bonten MJ. When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn? Semin Respir Infect 2003; 18:122-128.
132. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-1012. Convincing plea for an 'intelligent antibiotic therapy'.
133. Lepelletier D, Perron S, Huguenin H, et al. Should we screen for colonization to control the spread of multidrug resistant bacteria? Pathol Biol 2003; 51:464-468..
134. Pittet D. Hand hygiene: improved standards and practice for hospital care. Curr Opin Infect Dis 2003; 16:327-335.
135. Decousser JW, Pina P, Ghnassia JC, et al. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methiclillin-resistant Staphylococcus aureus carriage by mupirocin. Eur J Clin Microbiol Infect Dis 2003; 22:318-319.
136. Kitajima H. Prevention of methicillin-resistant Staphylococcus aureus infections in neonates. Pediatr Int 2003; 45:238-245.
137. Melamed R, Greenberg D, Porat N, et al. Successful control of an Acinetobacter baumannii outbreak in neonatal intensive care unit. J Hosp Infect 2003; 53:31-38.
138. Stelfox TH, Bates DW, Redelmeier DA, et al. Safety of patients isolated for infection control. JAMA 2003; 290:1899-1905. Interesting paper showing that a balance is needed between the 'intensity of' isolation procedures and quality of clinical management. Logic wins!
139. Toltzis P, Dul M, O'Riordan MA, et al. Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilli. Pediatr Infect Dis J 2003; 22:109-114.
140. Shorr AF, Susla GM, Kollef MH, et al. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32:137-143.
141. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs Vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aures nosocomial pneumonia. Chest 2003; 124:1789-1797.
142. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30:388-394.
143. Jantausch BA, Deville J, Adler S, et al. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 2003; 22:5164-5171.
144. Brogden KA, Ackermann M, McCray PB Jr, et al. Antimicrobial peptides in animals and their role in host defense. Int J Antimicrob Agents 2003; 22:465-478.
145. Lee YL, Cesario T, Wang Y, Shanbrom E, et al. Antibacterial activity of vegetables and juices. Nutrition 2003; 19:994-996.